Filing summary: Leap Therapeutics, Inc. Form 10-Q
Important identification discrepancy: The request metadata names Cypherpunk Technologies Inc., but the supplied filing is for Leap Therapeutics, Inc. (Nasdaq: LPTX), a biopharmaceutical company. This summary reflects the filing provided, for the quarter ended September 30, 2021.
Business context and reporting period
Leap develops cancer therapies; its lead clinical-stage candidate is DKN-01, an investigational antibody being studied in multiple cancer indications. The company has no FDA-approved product and has not generated product sales. BeiGene holds an option and license covering DKN-01 development and commercialization in Asia (excluding Japan), Australia, and New Zealand; Leap retains rights elsewhere.
Financial performance and position
Amounts below are in millions of U.S. dollars unless stated otherwise.
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| License revenue | $0.375 | $0.375 | $1.125 | $1.125 |
| Research and development expense | $10.077 | $5.369 | $24.090 | $15.322 |
| General and administrative expense | $2.438 | $2.514 | $7.973 | $7.188 |
| Operating loss | $(12.140) | $(7.508) | $(30.938) | $(21.385) |
| Net loss | $(11.139) | $(7.057) | $(29.799) | $(20.804) |
| Net loss per share | $(0.14) | $(0.09) | $(0.39) | $(0.58) |
- Cash and liquidity: Cash and cash equivalents were $124.771 million at September 30, 2021, versus $52.071 million at December 31, 2020. Current assets were $125.101 million and current liabilities $11.261 million.
- Cash flow, nine months: Operating activities used $24.441 million; financing provided $97.280 million, principally from the September 2021 public offering; cash increased by $72.700 million. There was no investing cash flow in 2021.
- Capital and obligations: The September offering generated approximately $96.828 million net proceeds. Total liabilities were $11.261 million; the filing reports no borrowings, and lease liabilities were $0.323 million. Noncancelable DKN-01 manufacturing commitments totaled $2.956 million.
- Equity: 87.837 million common shares were outstanding at quarter-end; 88.318 million were outstanding as of November 10, 2021. The filing also reports substantial outstanding warrants and options.
- Margins: Product-level or conventional operating margins are not meaningful given the company’s minimal license revenue and lack of product sales.
Material changes versus prior comparable periods
- Q3 R&D expense rose $4.708 million year over year, mainly from clinical-material manufacturing, patient-enrollment-related trial costs, and increased R&D headcount. Nine-month R&D expense rose $8.768 million; TRX518 spending declined as DKN-01 spending increased.
- Net loss increased by $4.082 million in Q3 and $8.995 million for the first nine months. Nine-month 2020 loss attributable to common stockholders also included preferred-stock dividends and beneficial-conversion and warrant-related charges, so its per-share comparison is affected by those items.
- Australian R&D incentive income increased to $1.584 million for the first nine months, from $0.343 million. Foreign-currency results shifted to a $0.410 million loss from a $0.189 million gain.
- The September 2021 offering brought in $96.828 million net and materially increased cash and the share count.
Outlook, commentary, and risks
- Management expected continued operating losses and said September 30 cash would fund operating expenses for at least 12 months from issuance of the financial statements. The company may seek additional financing or collaboration cost-sharing; without it, it may delay, reduce, or stop trials or other programs.
- Management planned increased R&D spending as DKN-01 development continued, subject to available funding. Timing and cost depend on clinical progress, enrollment, results, and regulatory requirements.
- The company reported initial positive Phase 2a DisTinGuish first-line data: among 25 HER2-negative gastric or gastroesophageal-junction patients who received a full cycle, reported overall response rate was 68.2%; reported response rates varied by DKK1 and PD-L1 groups. These are early clinical results, not evidence of regulatory approval or established efficacy.
- DKN-01 remains investigational and may never be approved. The filing identifies potential delays or adverse effects from COVID-19, clinical and regulatory uncertainty, financing needs, competition, manufacturing capacity, and intellectual-property risks. Management reported no material changes to the risk factors in its 2020 Form 10-K.
- Two European patent opposition matters concerning TRX518 were pending; the filing gives no clear resolution. No material legal proceedings were reported under the legal-proceedings item.
Most important facts for investors to verify
- Confirm the issuer: the provided filing is Leap Therapeutics, not Cypherpunk Technologies.
- Review the full clinical-trial disclosures and subsequent updates for DKN-01, including the small initial DisTinGuish cohort, trial design, follow-up, and patient subgroup data.
- Assess cash burn against management’s stated minimum 12-month runway, including planned R&D spending, manufacturing commitments, and the timing of Australian incentive receipts.
- Review the September offering terms and potential dilution from common shares, pre-funded warrants, other warrants, and stock options.
- Check the status of the BeiGene option and agreement, milestones and royalties, and the pending TRX518 patent oppositions.